A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.

Trial Details

NCT ID
NCT05710848
Phase
PHASE1 / PHASE2
Sponsor
SURGE Therapeutics
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • STM-416
Locations (sample)
  • Mesa, Arizona, United States|33.42227,-111.82264
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Bakersfield, California, United States|35.37329,-119.01871
  • Downey, California, United States|33.94001,-118.13257

Key Eligibility Criteria

  • Are aged 18 years or older;
  • Have a history of pathologically confirmed high-grade Ta or T1 NMIBC without CIS who have completed SOC previously, with recurrent papillary diseas…
  • Are considered high risk for recurrence;
  • Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →